{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
neratinib
to a specific field?
There is one exact (name or code) match for neratinib
Status:
US Approved Rx
(2017)
Source:
NDA208051
(2017)
Source URL:
First approved in 2017
Source:
NDA208051
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Neratinib (HKI-272) is a pan-HER inhibitor, this irreversible tyrosine kinase inhibitor binds and inhibits the tyrosine kinase activity of epidermal growth factor receptors, EGFR (or HER1), HER2 and HER4, which leads to reduced phosphorylation and activation of downstream signaling pathways. Neratinib is a modified form of the discontinued compound pelitinib, and was originally being develoAdditionally, phase II development of oral neratinib as a neoadjuvant therapy for breast cancer, as a second-line therapy for non-small cell lung cancer, and for other solid tumours is also in progress in numerous countries worldwide. ped by Wyeth (later Pfizer). Oral neratinib is awaiting approval as an extended adjuvant therapy for breast cancer in the EU and in the US. Blocking HER2 function by a small molecule kinase inhibitor, such as neratinib, represents an attractive alternate strategy for the growth inhibition of HER2-positive tumours.
Status:
US Approved Rx
(2017)
Source:
NDA208051
(2017)
Source URL:
First approved in 2017
Source:
NDA208051
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Neratinib (HKI-272) is a pan-HER inhibitor, this irreversible tyrosine kinase inhibitor binds and inhibits the tyrosine kinase activity of epidermal growth factor receptors, EGFR (or HER1), HER2 and HER4, which leads to reduced phosphorylation and activation of downstream signaling pathways. Neratinib is a modified form of the discontinued compound pelitinib, and was originally being develoAdditionally, phase II development of oral neratinib as a neoadjuvant therapy for breast cancer, as a second-line therapy for non-small cell lung cancer, and for other solid tumours is also in progress in numerous countries worldwide. ped by Wyeth (later Pfizer). Oral neratinib is awaiting approval as an extended adjuvant therapy for breast cancer in the EU and in the US. Blocking HER2 function by a small molecule kinase inhibitor, such as neratinib, represents an attractive alternate strategy for the growth inhibition of HER2-positive tumours.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
![Structure of 4-[[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino]-6-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-ethoxy-3-quinolinecarboxamide](/img/9fa7eaea-9d3e-41f7-8106-331f99ac7290.svg?size=200&context=gsihdegaqf)
![Structure of 6-Amino-4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-7-ethoxy-3-quinolinecarbonitrile](/img/40f34c4d-f2fc-4a17-9eb5-1ca27fa58b47.svg?size=200&context=gsihdegaqf)
![Structure of (2E)-N-[3-Cyano-7-ethoxy-4-[[4-(2-pyridinylmethoxy)phenyl]amino]-6-quinolinyl]-4-(dimethylamino)-2-butenamide](/img/4ad11ca2-b284-4d1c-99d2-ed2cf67dbefe.svg?size=200&context=gsihdegaqf)
![Structure of 4-[[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino]-7-ethoxy-6-(2-hydroxy-5-oxo-1-pyrrolidinyl)-3-quinolinecarbonitrile](/img/915cf5fd-ea9a-4a71-a02a-4854d2ed59a0.svg?size=200&context=gsihdegaqf)
